MX2019012525A - Proteinas de citomegalovirus modificadas y complejos estabilizados. - Google Patents

Proteinas de citomegalovirus modificadas y complejos estabilizados.

Info

Publication number
MX2019012525A
MX2019012525A MX2019012525A MX2019012525A MX2019012525A MX 2019012525 A MX2019012525 A MX 2019012525A MX 2019012525 A MX2019012525 A MX 2019012525A MX 2019012525 A MX2019012525 A MX 2019012525A MX 2019012525 A MX2019012525 A MX 2019012525A
Authority
MX
Mexico
Prior art keywords
hcmv
complexes
stabilized complexes
modified cytomegalovirus
modified
Prior art date
Application number
MX2019012525A
Other languages
English (en)
Inventor
MALITO Enrico
CHANDRAMOULI Sumana
Carfi Andrea
Bottomley Matthew
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2019012525A publication Critical patent/MX2019012525A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material
    • C12N2710/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen polipéptidos mutantes del complejo pentamérico de citomegalovirus humano (HCMV), los procedimientos para prepararlos y su uso en los complejos y las composiciones de proteínas de HCMV. En particular, se describe el uso de los polipéptidos de HCMV modificados para estabilizar los complejos de HCMV o desenmascarar un epítopo pentamérico.
MX2019012525A 2017-04-19 2018-04-18 Proteinas de citomegalovirus modificadas y complejos estabilizados. MX2019012525A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762487065P 2017-04-19 2017-04-19
US201762504059P 2017-05-10 2017-05-10
US201762523465P 2017-06-22 2017-06-22
PCT/IB2018/000491 WO2018193307A1 (en) 2017-04-19 2018-04-18 Modified cytomegalovirus proteins and stabilized complexes

Publications (1)

Publication Number Publication Date
MX2019012525A true MX2019012525A (es) 2019-12-05

Family

ID=62713027

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012525A MX2019012525A (es) 2017-04-19 2018-04-18 Proteinas de citomegalovirus modificadas y complejos estabilizados.

Country Status (6)

Country Link
US (1) US20230248820A1 (es)
EP (1) EP3612550A1 (es)
CN (1) CN111094323B (es)
CA (1) CA3060019A1 (es)
MX (1) MX2019012525A (es)
WO (1) WO2018193307A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021014385A1 (en) 2019-07-24 2021-01-28 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920701453A (ko) 1989-03-17 1992-08-11 미리엄 디. 멕코나헤이 유전자발현의 외부조절
US5362865A (en) 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
US7704510B2 (en) 2006-06-07 2010-04-27 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
US9439960B2 (en) * 2007-10-10 2016-09-13 The Trustees Of Princeton University Cytomegalovirus vaccines and methods of production
CN102203133B (zh) 2008-07-16 2015-01-07 生物医学研究学会 人巨细胞病毒中和抗体及其应用
EP2320945A4 (en) 2008-07-30 2013-02-27 Emergent Biosolutions Inc STABLE VACCINE FORMULATIONS AGAINST ANTHRAX
SG178954A1 (en) 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
GB2513768B (en) 2012-07-06 2015-04-15 Novartis Ag Complexes of cytomegalovirus proteins and nucleic acids encoding such proteins
CN102816246B (zh) * 2012-09-04 2014-07-23 成都蓉生药业有限责任公司 一种人巨细胞病毒免疫原融合蛋白及其制备方法和用途
BR112015008930A2 (pt) 2012-10-30 2017-11-21 Redvax Gmbh vacinas baseadas em partícula recombinante contra a infecção por citomegalovírus humano
EP3139953A1 (en) 2014-05-08 2017-03-15 Pfizer Inc. Means and methods for treating cmv
BE1023213B1 (fr) * 2014-05-27 2016-12-21 Glaxosmithkline Biologicals Sa Complexes issus du cytomegalovirus et leurs utilisations
EP3048114A1 (en) * 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof

Also Published As

Publication number Publication date
WO2018193307A1 (en) 2018-10-25
CA3060019A1 (en) 2018-10-25
CN111094323A (zh) 2020-05-01
CN111094323B (zh) 2024-02-06
US20230248820A1 (en) 2023-08-10
EP3612550A1 (en) 2020-02-26

Similar Documents

Publication Publication Date Title
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
PH12018501882A1 (en) Binding proteins and methods of use thereof
MX2020011257A (es) Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
MX2022001222A (es) Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y metodos para usarlos.
MX2021004273A (es) Proteinas de citomegalovirus modificadas y complejos estabilizados.
MX2018000621A (es) Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y metodos de uso de los mismos.
MX2021003475A (es) Metodos de purificacion de proteinas.
WO2015132675A3 (en) Methods and compositions for modifying the immune response
MX2022011973A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
MX2019012525A (es) Proteinas de citomegalovirus modificadas y complejos estabilizados.
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
MX2021008005A (es) Bibliotecas de peptidos y metodos de uso de las mismas.
PH12019502185A1 (en) Hydrolysed vegetable proteins suitable for use in baby food